Jennifer L Grant1, Patricia Agaba2,3, Placid Ugoagwu2, Auwal Muazu2, Jonathan Okpokwu2, Samuel Akpa2, Stephen Machenry2, Godwin Imade2,4, Oche Agbaji2,5, Chloe L Thio6, Robert Murphy1, Claudia Hawkins1. 1. Department of Medicine, Division of Infectious Diseases, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 2. HIV Care and Treatment Centre, Jos University Teaching Hospital, Jos, Nigeria. 3. Department of Family Medicine, University of Jos and Jos University Teaching Hospital, Jos, Nigeria. 4. Department of Obstetrics and Gynaecology, University of Jos and Jos University Teaching Hospital, Jos, Nigeria. 5. Department of Medicine, University of Jos and Jos University Teaching Hospital, Jos, Nigeria. 6. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University, Baltimore, MD, USA.
Abstract
BACKGROUND: There are limited data from sub-Saharan Africa on long-term liver fibrosis changes in HIV- and HIV/HBV-infected individuals. OBJECTIVES: To assess the effects of ART on liver stiffness measurement (LSM) using transient elastography (TE) in HIV- and HIV/HBV-infected Nigerian adults and examine factors associated with fibrosis regression. METHODS: We included ART-naive HIV- and HIV/HBV-infected adults (≥18 years) enrolled in a prospective, longitudinal study of liver disease between July 2011 and February 2015 at Jos University Teaching Hospital HIV Care and Treatment Centre in Nigeria. Patients initiated ART and had TE at baseline and follow-up (year 3). LSM cut-offs for Metavir scores were 5.9, 7.6 and 9.4 kPa for moderate fibrosis, advanced fibrosis and cirrhosis, respectively. We used multivariable regression to identify factors associated with TE (≥1 Metavir) stage decline. RESULTS: A total of 106 HIV- and 71 HIV/HBV-infected patients [70.5% female and median age = 34 years (IQR = 29-42 years)] were studied. Baseline LSM and median LSM decline were significantly higher in HIV/HBV- versus HIV-infected patients; 41% of HIV/HBV-infected patients regressed ≥1 Metavir stage versus 17% of HIV-infected patients (P < 0.01); LSM scores at year 3 were not significantly different between HIV- and HIV/HBV-infected patients. In multivariable analyses, patients with baseline CD4+ T cells ≥200 (versus <200) cells/mm3 and lower BMIs were more likely to experience LSM stage decline. CONCLUSIONS: HBV coinfection does not attenuate LSM declines in HIV-infected patients after ART initiation despite being a risk factor for more advanced liver disease prior to therapy. The inverse association between BMI and TE stage decline needs further investigation.
BACKGROUND: There are limited data from sub-Saharan Africa on long-term liver fibrosis changes in HIV- and HIV/HBV-infected individuals. OBJECTIVES: To assess the effects of ART on liver stiffness measurement (LSM) using transient elastography (TE) in HIV- and HIV/HBV-infected Nigerian adults and examine factors associated with fibrosis regression. METHODS: We included ART-naive HIV- and HIV/HBV-infected adults (≥18 years) enrolled in a prospective, longitudinal study of liver disease between July 2011 and February 2015 at Jos University Teaching Hospital HIV Care and Treatment Centre in Nigeria. Patients initiated ART and had TE at baseline and follow-up (year 3). LSM cut-offs for Metavir scores were 5.9, 7.6 and 9.4 kPa for moderate fibrosis, advanced fibrosis and cirrhosis, respectively. We used multivariable regression to identify factors associated with TE (≥1 Metavir) stage decline. RESULTS: A total of 106 HIV- and 71 HIV/HBV-infectedpatients [70.5% female and median age = 34 years (IQR = 29-42 years)] were studied. Baseline LSM and median LSM decline were significantly higher in HIV/HBV- versus HIV-infectedpatients; 41% of HIV/HBV-infectedpatients regressed ≥1 Metavir stage versus 17% of HIV-infectedpatients (P < 0.01); LSM scores at year 3 were not significantly different between HIV- and HIV/HBV-infectedpatients. In multivariable analyses, patients with baseline CD4+ T cells ≥200 (versus <200) cells/mm3 and lower BMIs were more likely to experience LSM stage decline. CONCLUSIONS: HBV coinfection does not attenuate LSM declines in HIV-infectedpatients after ART initiation despite being a risk factor for more advanced liver disease prior to therapy. The inverse association between BMI and TE stage decline needs further investigation.
Authors: P Miailhes; P Pradat; M Chevallier; K Lacombe; F Bailly; L Cotte; M-A Trabaud; A Boibieux; J Bottero; C Trepo; F Zoulim Journal: J Viral Hepat Date: 2011-01 Impact factor: 3.728
Authors: Robert P Myers; Gilles Pomier-Layrargues; Richard Kirsch; Aaron Pollett; Melanie Beaton; Mark Levstik; Andres Duarte-Rojo; David Wong; Pam Crotty; Magdy Elkashab Journal: J Hepatol Date: 2011-10-23 Impact factor: 25.083
Authors: Chloe L Thio; Eric C Seaberg; Richard Skolasky; John Phair; Barbara Visscher; Alvaro Muñoz; David L Thomas Journal: Lancet Date: 2002-12-14 Impact factor: 79.321
Authors: Christopher J Hoffmann; Jennifer D Hoffmann; Caroline Kensler; Martin van der Watt; Tanvier Omar; Richard E Chaisson; Neil A Martinson; Ebrahim Variava Journal: PLoS One Date: 2015-02-10 Impact factor: 3.240